T1D market in seven major markets to reach $9.9b by 2033

Thanks to the expected introduction of several late-stage pipeline products.

The type 1 diabetes (T1D) market across the seven major markets is projected to expand to $9.9b in 2033 from $2.2b in 2023, according to GlobalData.

This means a compound annual growth rate of 13.3% across the US, France, Germany, Italy, Spain, the UK, and Japan. This will be driven by the anticipated introduction of several late-stage pipeline products, including multiple immunomodulatory agents, during the forecast period.

GlobalData said the US is the largest T1D market in the seven countries, accounting for 80.4% of global sales in 2023. It is expected to gain further market share during the forecast period, accounting for 91.6% of the major markets’ T1D sales by 2033.

The company noted that there may still be some challenges that will slow growth. These include high financial burden of immunomodulatory agents, which means insurance and reimbursement restrictions will impact drug sales, as well as the high failure rate of clinical trials developing disease-modifying therapeutics in the T1D space.